RT Journal Article
SR Electronic
T1 Long-term Response After Stopping Immunotherapy in a Patient With Metastatic Renal Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1805
OP 1810
DO 10.21873/invivo.12441
VO 35
IS 3
A1 BOGDAN HAINEALA
A1 ANCA ZGURA
A1 CAMELIA DIACONU
A1 CLAUDIA MEHEDINTU
A1 XENIA BACINSCHI
A1 RODICA MARICELA ANGHEL
YR 2021
UL http://iv.iiarjournals.org/content/35/3/1805.abstract
AB Background/Aim: Kidney cancers account for about 2% of human malignancies. In recent decades, the incidence of this cancer type has gradually increased, mainly due to advances in imaging. The metastatic potential of these cancers is significant: a quarter of patients will immediately present with metastases and more than one third of patients treated with nephrectomy for a localized disease will develop metastases during their course. In total, more than half of patients will suffer from the consequences of metastasis. The median survival at this stage is only thirteen months, so the therapeutic challenge is immense. Case Report: The present case report describes a case of left renal clear cell carcinoma with brain, lung, right adrenal, bone and lymph node metastases in a 55-year-old male. The patient received only one line of anticancer treatment with sunitinib, which could not be continued due to haemorrhagic manifestations in brain metastases. The treatment was changed with immunotherapy which showed its effect even if it was stopped due to the patient wishes in the context of the COVID-19 epidemic. Conclusion: Immunotherapy opens the doors to a new era in treatment of metastatic renal cancer and shows efficiency even after it has been stopped.